VERI vs. MXCT, III, TCX, OABI, PESI, AHG, RGP, RCMT, EDHL, and MIMI
Should you be buying Veritone stock or one of its competitors? The main competitors of Veritone include MaxCyte (MXCT), Information Services Group (III), Tucows (TCX), OmniAb (OABI), Perma-Fix Environmental Services (PESI), Akso Health Group (AHG), Resources Connection (RGP), RCM Technologies (RCMT), Everbright Digital (EDHL), and Mint Incorporation (MIMI). These companies are all part of the "business services" industry.
Veritone vs. Its Competitors
MaxCyte (NASDAQ:MXCT) and Veritone (NASDAQ:VERI) are both small-cap business services companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.
68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 39.2% of Veritone shares are owned by institutional investors. 3.3% of MaxCyte shares are owned by insiders. Comparatively, 26.6% of Veritone shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
MaxCyte presently has a consensus target price of $7.50, suggesting a potential upside of 237.84%. Veritone has a consensus target price of $4.50, suggesting a potential upside of 204.05%. Given MaxCyte's stronger consensus rating and higher possible upside, equities analysts plainly believe MaxCyte is more favorable than Veritone.
Veritone has a net margin of -32.75% compared to MaxCyte's net margin of -110.92%. Veritone's return on equity of 0.00% beat MaxCyte's return on equity.
Veritone has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Veritone, indicating that it is currently the more affordable of the two stocks.
In the previous week, Veritone had 2 more articles in the media than MaxCyte. MarketBeat recorded 4 mentions for Veritone and 2 mentions for MaxCyte. Veritone's average media sentiment score of 0.12 beat MaxCyte's score of 0.00 indicating that Veritone is being referred to more favorably in the news media.
MaxCyte has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, Veritone has a beta of 2.64, indicating that its share price is 164% more volatile than the S&P 500.
Summary
Veritone beats MaxCyte on 11 of the 16 factors compared between the two stocks.
Get Veritone News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VERI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Veritone Competitors List
Related Companies and Tools
This page (NASDAQ:VERI) was last updated on 7/9/2025 by MarketBeat.com Staff
Free VERI Stock Alerts